Redeye provides a brief comment on Oncopeptides' decision to submit a type II variation to expand the Pepaxti label to include third-line treatment. Given this will take at least one year, it will not impact the near-term commercialisation of Pepaxti. It could increase the total addressable market long-term, however.
LÄS MER
